NYSE : GSK
GSK plc — Key statistics
Healthcare · Drug Manufacturers - General · United Kingdom
Last price 48.68 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 97.25B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 97.36B |
| Enterprise Value | 124.80B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | Nov 13, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 4.01B |
| Shares Change (YoY) | -1.37% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 84.54% |
| Float | 3.89B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 17.16 |
| Forward PE | 9.85 |
| PS Ratio | 2.20 |
| Forward PS | 2.09 |
| PB Ratio | 4.03 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 9.86 |
| P/OCF Ratio | 8.20 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 21.74 |
| EV / Sales | 2.82 |
| EV / EBITDA | 8.54 |
| EV / EBIT | 9.62 |
| EV / FCF | 12.61 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.86 |
| Quick Ratio | 0.55 |
| Debt / Equity | 1.30 |
| Debt / EBITDA | 2.11 |
| Debt / FCF | 3.17 |
| Interest Coverage | 14.94 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 28.27% |
| Return on Assets (ROA) | 9.24% |
| Return on Invested Capital (ROIC) | 24.61% |
| Return on Capital Employed (ROCE) | 19.28% |
| Weighted Average Cost of Capital (WACC) | 4.98% |
| Revenue Per Employee | $666,241 |
| Profits Per Employee | $86,421 |
| Employee Count | 66,841 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 1.42 |
Taxes
| Measure | Value |
|---|
| Income Tax | 744.79M |
| Effective Tax Rate | 10.42% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.28 |
| 52-Week Price Change | +4.95% |
| 50-Day Moving Average | 49.37 |
| 200-Day Moving Average | 52.34 |
| Relative Strength Index (RSI) | 49.37 |
| Average Volume (20 Days) | 5,742,740 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 14.58M |
| Short Previous Month | 14.65M |
| Short % of Shares Out | 0.73% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.86 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 44.53B |
| Gross Profit | 32.86B |
| Operating Income | 13.05B |
| Pretax Income | 7.15B |
| Net Income | 5.78B |
| EBITDA | 14.71B |
| EBIT | 13.05B |
| Earnings Per Share (EPS) | $2.86 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.93B |
| Total Debt | 31.60B |
| Net Cash | -27.67B |
| Net Cash Per Share | -$6.90 |
| Equity (Book Value) | 24.38B |
| Book Value Per Share | 6.21 |
| Working Capital | -3.75B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 11.96B |
| Capital Expenditures | -2.01B |
| Depreciation & Amortization | 1.67B |
| Net Borrowing | 8.44B |
| Free Cash Flow | 9.96B |
| FCF Per Share | $2.48 |
Margins
| Measure | Value |
|---|
| Gross Margin | 73.79% |
| Operating Margin | 29.31% |
| Pretax Margin | 16.05% |
| Profit Margin | 12.97% |
| EBITDA Margin | 33.02% |
| EBIT Margin | 29.31% |
| FCF Margin | 22.13% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $1.80 |
| Dividend Yield | 3.67% |
| Dividend Growth (YoY) | 7.71% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 63.18% |
| FCF Payout Ratio | 72.81% |
| Buyback Yield | 1.37% |
| Shareholder Yield | 5.04% |
| Earnings Yield | 5.83% |
| FCF Yield | 10.15% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $59.12 |
| Price Target Difference | 20.37% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 3.76% |
| EPS Growth Forecast (3Y) | 4.52% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:1.25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.98 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |